Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Bamco Inc. NY

Bamco Inc. NY decreased its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 91.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,000 shares of the biotechnology company's stock after selling 809,341 shares during the quarter. Bamco Inc. NY owned approximately 0.08% of Rocket Pharmaceuticals worth $943,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Covestor Ltd raised its position in shares of Rocket Pharmaceuticals by 33,166.7% during the 4th quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 1,990 shares during the period. Signaturefd LLC grew its stake in shares of Rocket Pharmaceuticals by 319.8% in the 4th quarter. Signaturefd LLC now owns 4,916 shares of the biotechnology company's stock worth $62,000 after buying an additional 3,745 shares in the last quarter. Harbour Investments Inc. increased its stake in Rocket Pharmaceuticals by 51.9% during the fourth quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company's stock worth $68,000 after acquiring an additional 1,840 shares during the last quarter. KBC Group NV raised its position in Rocket Pharmaceuticals by 159.6% during the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 3,366 shares during the period. Finally, Virtus ETF Advisers LLC lifted its stake in shares of Rocket Pharmaceuticals by 40.4% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,656 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 1,628 shares during the last quarter. Institutional investors own 98.39% of the company's stock.

Rocket Pharmaceuticals Stock Down 1.0 %

Rocket Pharmaceuticals stock traded down $0.07 during midday trading on Friday, hitting $6.97. 3,138,101 shares of the company's stock were exchanged, compared to its average volume of 1,411,907. Rocket Pharmaceuticals, Inc. has a 12 month low of $4.55 and a 12 month high of $26.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The company has a market cap of $744.30 million, a PE ratio of -2.53 and a beta of 1.02. The firm has a 50-day moving average of $7.15 and a two-hundred day moving average of $10.70.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.03. During the same period in the prior year, the business earned ($0.66) earnings per share. As a group, analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Rocket Pharmaceuticals news, CFO Aaron Ondrey sold 7,489 shares of the business's stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $5.29, for a total transaction of $39,616.81. Following the sale, the chief financial officer now owns 129,650 shares of the company's stock, valued at approximately $685,848.50. The trade was a 5.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Gaurav Shah purchased 20,000 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was bought at an average cost of $5.08 per share, with a total value of $101,600.00. Following the acquisition, the chief executive officer now owns 792,680 shares of the company's stock, valued at approximately $4,026,814.40. The trade was a 2.59 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 28.50% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on RCKT. Canaccord Genuity Group decreased their price target on Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. The Goldman Sachs Group lowered their target price on shares of Rocket Pharmaceuticals from $15.00 to $13.00 and set a "neutral" rating for the company in a report on Friday. Scotiabank increased their price objective on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 3rd. Chardan Capital cut their price objective on Rocket Pharmaceuticals from $54.00 to $45.00 and set a "buy" rating on the stock in a research report on Friday. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $42.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday, April 9th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Rocket Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $41.09.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.